EQT Life Sciences leads USD 75 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington's disease

Alicia Secor, M.B.A., Atalanta's President and Chief Executive Officer, said: "We're excited by the support we've received from this strong group of investors, led by EQT Life Sciences. This Series B will support a path to the clinic for two programs for serious neurological diseases that today lack disease-modifying therapies: KCNT1-related epilepsy and Huntington's disease. We're diligently progressing these medicines toward IND submissions next year so that we can start our Phase 1 trials and reach patients who are waiting."

Huntington's, 28/01/2025 (informazione.news - comunicati stampa - salute e benessere)

Alicia Secor , M.B.A., Atalanta's President and Chief Executive Officer, said: "We're excited by the support we've received from this strong group of investors, led by EQT Life Sciences. This Series B will support a path to the clinic for two programs for serious neurological diseases that today lack disease-modifying therapies: KCNT1-related epilepsy and Huntington's disease. We're diligently progressing these medicines toward IND submissions next year so that we can start our Phase 1 trials and reach patients who are waiting."

"Atalanta's di-siRNA technology has shown promising ability to durably and evenly silence disease-promoting genes throughout previously inaccessible regions of the brain and spinal cord - opening a wide range of treatment possibilities for devastating neurological diseases," said Arno de Wilde , M.D., Ph.D., M.B.A., Managing Director at EQT Life Sciences. "EQT is proud to lead this investment in Atalanta's future as part of such a high-quality investor syndicate, and we look forward to partnering with Alicia and Atalanta's leadership to support their continued success."

Alongside EQT Life Sciences, the financing was co-led by Sanofi Ventures, with participation from other new investors RiverVest Venture Partners, abrdn, Inc., Mirae Asset Financial Group and existing investor F-Prime Capital. The Series B financing brings Atalanta's total capital generated to date from financings and partnerships with Genentech and Biogen to USD 240 million .

EQT Press Office, press@eqtpartners.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/eqt-life-sciences-leads-usd-75-million-series-b-in-atalanta-therapeutics--a-biotech-firm-developing-,c4096665

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-leads-usd-75-million-series-b-in-atalanta-therapeutics-a-biotech-firm-developing-treatments-for-epilepsy-and-huntingtons-disease-302361914.html